Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health
Genexis Health
Compounds
Neuro

Semax

Also known as ACTH (4-7) Pro-Gly-Pro

Phase 2 trials

Tested in humans for efficacy at a modest scale. Enough to show a signal and characterise short-term tolerability, not enough to establish safety or durability. Most compounds that reach this stage still fail.

Not approved anywhere No regulator has licensed this compound for any indication. It has no established safe dose in humans.
Illustration only. Not a photograph of a product, and not an offer of supply — Genexis Health does not sell or supply Semax.

What it is

A heptapeptide analogue of a fragment of ACTH, developed in Russia where it is a registered medicine. It is not licensed in the UK, EU or US.

How it is thought to work

Reported to increase BDNF and NGF expression and to influence monoamine systems, without the hormonal effects of full-length ACTH.

What the studies found

  • Registered in Russia for stroke and cognitive indications

    Russian clinical studies reported benefit in ischaemic stroke and cognitive disorders, supporting registration there.

  • Neurotrophic effects in animal models

    Animal work supports effects on BDNF expression and neuroprotection in ischaemia models.

What the evidence does not show

  • The clinical evidence is almost entirely Russian-language and has not been replicated to Western regulatory standards.
  • No major regulator outside Russia has assessed it.
  • Claims about cognitive enhancement in healthy people are not what the studies examined.

Reported risks and adverse effects

  • Reported as well tolerated in the studies that exist, which are of limited methodological quality.
  • No long-term safety data meeting Western standards.

This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.

Regulatory status

A registered medicine in Russia. Not approved in the UK, EU or US.